New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
05:55 EDTVSTM, VSTM, ONCY, ONCY, RIGL, RIGL, CELG, CELG, OXBT, OXBT, GALE, GALE, GTXI, GTXI, AFFY, AFFYBiotech Industry Organization to host a conference
15th Annual BIO CEO & Investor Conference is being held in New York on February 11-12.
News For CELG;OXBT;GALE;GTXI;AFFY;VSTM;ONCY;RIGL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
09:17 EDTGALEOn The Fly: Pre-market Movers
Subscribe for More Information
07:03 EDTVSTMVerastem presents 'encouraging' data from VS-6063 study
Verastem announced four poster presentations at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 18 - 21, 2014, in Barcelona, Spain. “We are pleased that the safety and pharmacokinetic profile observed in our Phase 1 study of VS-6063 in Japanese patients was consistent with that seen in the US Phase 1 study, permitting the inclusion of Japanese sites in COMMAND, the registration-directed study of VS-6063 in patients with mesothelioma following frontline chemotherapy. Also, we noted that the one patient in the Phase 1 study with relapsed mesothelioma appeared to receive clinical benefit with disease stabilization of almost 6 months,” said Dr. Joanna Horobin, Verastem Chief Medical Officer. “Relapsed mesothelioma is highly aggressive with reported median progression free survival of six weeks in controlled clinical trials. The encouraging data reported here from the combination of VS‐6063 and VS‐5584 in pre-clinical models of mesothelioma offers a novel therapeutic approach in this setting. We look forward to initiating a new clinical study evaluating the combination of these two agents in patients with relapsed mesothelioma in the first quarter of 2015.”
06:04 EDTCELGCelgene receives positive CHMP opinion for OTEZLA
Celgene announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion for OTEZLA, the company’s oral selective inhibitor of phosphodiesterase 4, or PDE4, in two therapeutic indications, for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or, who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light, or PUVA; alone or in combination with Disease Modifying Antirheumatic Drugs, or DMARD, for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
November 20, 2014
16:22 EDTGALEGalena announces $55M purchase agreement with Lincoln Park Capital
Galena Biopharma announced the execution of a purchase agreement for up to $55M with Lincoln Park Capital Fund, a Chicago-based institutional investor. Under the terms of the purchase agreement dated November 18, LPC initially purchased $5M of Galena common stock at a price of $2.00 per share, 9% higher than the market close as of November 18, 2014. Thereafter, at its sole discretion, Galena may sell up to $50M worth of common stock to LPC over the 36-month term of the purchase agreement, subject to the conditions and limitations set forth in the purchase agreement. Under the terms of the purchase agreement, LPC will not cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of Galena common stock and is obligated to purchase at times and amounts controlled by the company. In consideration for entering into the agreement the company issued shares of its common stock to LPC as a commitment fee. Galena plans to use the proceeds received for its commercial and product development activities and for other working capital and general corporate purposes.
November 19, 2014
09:39 EDTCELGCelgene management to meet with ISI Group
Subscribe for More Information
07:44 EDTONCYStifel to hold a conference
Subscribe for More Information
November 18, 2014
07:37 EDTGALEStifel to hold a conference
Subscribe for More Information
07:34 EDTCELGCelgene presents long-term OTEZLA data at ACR/ARHP meeting
Celgene announced that results from long-term efficacy and safety analyses of OTEZLA from the open-label phase of two PALACE phase III clinical trials were presented at the 2014 American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting in Boston. OTEZLA is the Company’s oral, selective inhibitor of phosphodiesterase 4, approved by the U.S. FDA for the treatment of adult patients with active psoriatic arthritis and for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In PALACE 1, 84 percent of patients who completed one year of 30 mg twice daily therapy continued to receive OTEZLA at two years. Improvements in efficacy measures observed at 52 weeks were sustained through 104 weeks of treatment. At week 104, among patients receiving OTEZLA 30 mg twice daily, the ACR20 response rate was 65.3 percent. ACR50 and 70 response rates were 34.0 percent and 19.6 percent, respectively, at week 104. Similar findings were observed in PALACE 4. In this trial, nearly 84 percent of DMARD-naïve patients who completed one year of OTEZLA 30 mg twice daily monotherapy continued to receive OTEZLA at two years. At week 104, among patients treated with OTEZLA 30 mg twice daily monotherapy, an ACR20, 50 and 70 response was reached by 61.4 percent, 40.7 percent and 19.2 percent of patients, respectively. In both PALACE 1 and PALACE 4, changes in other efficacy measures—including the HAQ-DI, which assesses improvements in physical function, and swollen and tender joint counts—were also generally sustained between weeks 52 and 104 with continued OTEZLA treatment. In PALACE 4, treatment with OTEZLA in patients with pre-existing enthesitis or dactylitis, two key manifestations of psoriatic arthritis, resulted in improvements in enthesitis and dactylitis that were sustained through 104 weeks of treatment.
07:09 EDTGALEGalena completes enrollment in GALE-401 Phase 2 clinical trial
Galena Biopharma announced the completion of enrollment in the GALE-401, or Anagrelide Controlled Release, Phase 2 Clinical Trial. The Phase 2, clinical proof-of-concept study is treating 18 patients with elevated platelet counts in myeloproliferative neoplasms, or MPNs, including Essential Thrombocythemia, or ET, Polycythemia Vera, or PV, and Primary Myelofibrosis, or PMF. The Phase 2 trial is an open-label, single-arm, multicenter study designed to confirm the platelet-lowering activity of GALE-401 in patients with MPNs, to assess safety and tolerability, and to measure plasma concentrations of anagrelide. The platelet lowering ability of GALE-401 will be measured by the proportion of patients that achieve a complete or partial platelet response for at least four weeks during 24 weeks of treatment. With enrollment complete, patients will now be followed for platelet response while they continue study treatment.
November 17, 2014
07:16 EDTCELG, VSTMMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 14, 2014
17:07 EDTCELGSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
07:14 EDTCELGAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 12, 2014
08:13 EDTVSTMBoston Biotech to hold a conference
Subscribe for More Information
November 11, 2014
09:17 EDTGALEOn The Fly: Pre-market Movers
UP AFTER EARNINGS: FMSA Holdings (FMSA), up 4.7% following third quarter results. ALSO HIGHER: AVEO Pharmaceuticals (AVEO), up 7.6% after entering agreement with Ophthotech (OPHT) to license tivozanib... Ophthotech is 2.1% higher in pre-market trading... Galena Biopharma (GALE), up 3.6% after first patient dosed in NeuVax and Herceptin combination Phase 2 trial... Yamana Gold (AUY), up 3% after being upgraded to Overweight from Neutral at HSBC... Ambac Financial (AMBC), up 3.1% after being upgraded to Neutral from Sell at MKM Partners... China Finance (JRJC), up 12.4% after announcing a new partnership with Great Wall Securities... Zynga (ZNGA), up 5.7% after being upgraded on mobile business growth at Jefferies... Fiat Chrysler (FCAU), up 2.2% after being initiated with a Conviction Buy at Goldman. DOWN AFTER EARNINGS: Applied Optoelectronics (AAOI), down 10.7%... Ekso Bionics (EKSO), down 2.2%. ALSO LOWER: Alibaba Group (BABA), down 1.6% following comments made by vice chairman Joseph Tsai in an interview.
07:06 EDTGALEGalena doses first patient in NeuVax, Herceptin combination Phase 2 trial
Subscribe for More Information
November 10, 2014
13:18 EDTGALEGalena terminates Brian Hamilton as Chief Medical Officer
Subscribe for More Information
07:19 EDTCELGCredit Suisse to hold a conference
Subscribe for More Information
07:16 EDTGTXIGTx reports Q3 EPS (6c), consensus (11c)
07:10 EDTGTXIGTx announces $43.4M in a private placement
Subscribe for More Information
07:09 EDTGTXIGTx announces $43.4M private placement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use